Spartina® (Tirzepatide) Effectiveness and Safety Evaluation
NCT ID: NCT07262762
Last Updated: 2025-12-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
175 participants
OBSERVATIONAL
2025-11-11
2026-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. Is Spartina® (Tirzepatide) effective in the treatment of obesity and overweight?
2. Is Spartina® (Tirzepatide) safe in the treatment of obesity and overweight?
In this study, there is no comparison group. Participants receive Spartina® (Tirzepatide)
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Willingness for signing and having signed the informed consent form
3. BMI ≥30 kg/m² or ≥27 kg/m² with ≥1 weight-related comorbidity
Exclusion Criteria
2. Type 1 diabetes mellitus
3. Any condition or circumstance that might pose a risk to the subject or interfere with the ability to acquire satisfactory clinical data
4. Pregnancy or breast-feeding
5. Personal or family history of medullary thyroid carcinoma (MTC) or patients with multiple endocrine neoplasia syndrome type 2 (MEN 2)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cinnagen
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Akbar Aliasgarzadeh Clinic
Tabriz, East Azerbaijan Province, Iran
Dr. Mohammadhossein Dabbaghmanesh Clinic
Shiraz, Fars, Iran
Behrang Motamed Clinic
Rasht, Gilan Province, Iran
Seyed Mojtaba Mehrdad Clinic
Rasht, Gilan Province, Iran
Mansoor Siavash Dastjerdi Clinic
Isfahan, Isfahan, Iran
Shokoofeh Bonakdaran Clininc
Mashhad, Khorasan Razavi, Iran
Sari Diabetes Research Center
Sari, Mazandaran, Iran
Alireza Esteghamati clinic
Tehran, Tehran Province, Iran
Farzad Hadaegh Clininc
Tehran, Tehran Province, Iran
Imam Khomeini Hospital
Tehran, Tehran Province, Iran
Iran University Endocrinology Research Center
Tehran, Tehran Province, Iran
Mohammadreza Mohajeri Tehrani Clininc
Tehran, Tehran Province, Iran
Khorshid Clinic
Yazd, Yazd Province, Iran
Hajieh Bibi Shahbazian Clinic
Ahvāz, , Iran
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TIR.CIN.AE.IV.04
Identifier Type: -
Identifier Source: org_study_id